SCHEMBL46309

SCHEMBL46309

Cc1ccc(N2CCOCC2)nc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.64
GAA P10253 3/20 0.64
HPGD P15428 3/20 0.64
HSD17B10 Q99714 3/20 0.64
MEN1 O00255 2/20 0.64
MAPT P10636 2/20 0.64
KMT2A Q03164 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
KDM4E B2RXH2 2/20 0.64
LMNA P02545 1/20 0.64
HTT P42858 1/20 0.64
RECQL P46063 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
CYP1A2 P05177 3/20 0.58
CYP2C19 P33261 1/20 0.58
CYP11B1 P15538 1/20 0.57
CYP11B2 P19099 1/20 0.57
CYP2C9 P11712 1/20 0.55
CNR2 P34972 4/20 0.54
GRIN2D O15399 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13724949 0.93 ALDH1A1 (0.57) ALDH1A1GAAHPGDHSD17B10MEN1
SCHEMBL12864090 0.86 CNR2 (0.62) ALDH1A1GAAHPGDHSD17B10MEN1
SCHEMBL21424864 0.86 GRIN2D (0.59) ALDH1A1GAAHPGDHSD17B10MEN1
SCHEMBL806544 0.82 CNR2 (0.59) ALDH1A1MAPTLMNACNR2GRIN2D
SCHEMBL31415358 0.82 CNR2 (0.59) ALDH1A1MAPTLMNACNR2GRIN2D
SCHEMBL11988476 0.82 GRIN2D (0.56) ALDH1A1GAAHPGDHSD17B10MEN1
SCHEMBL82447 0.81 CNR2 (0.62) ALDH1A1MAPTLMNACNR2GRIN2D
SCHEMBL1108644 0.81 CNR2 (0.62) ALDH1A1MAPTLMNACNR2GRIN2D
SCHEMBL14734000 0.80 GPR119 (0.55) ALDH1A1GAAHPGDHSD17B10MEN1
SCHEMBL2000301 0.79 GRIN2D (0.53) ALDH1A1GAAHPGDHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 584 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350090-B1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2015-06-03 EP claimed
US-8263606-B2 Spiro-oxindole compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2012-09-11 US claimed
US-20100137299-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2010-06-03 US claimed
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-07-11 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
WO-2024107393-A1 TRICYCLIC COMPOUNDS SCHRÖDINGER, INC. (US) 2024-05-23 WO disclosed
WO-2024054469-A1 ISOQUINOLONES AS PI3K INHIBITORS ONKURE, INC. (US) 2024-03-14 WO disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20070191447-A1 Novel heterocyclic compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 US disclosed
WO-2007059610-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-05-31 WO disclosed
WO-2007059611-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-05-31 WO disclosed
US-20070055065-A1 N-sulphonylated amino acid derivatives, method for the production and use thereof CURACYTE CHEMISTRY GMBH (DE) 2007-03-08 US disclosed
US-20070055065-A1 N-sulphonylated amino acid derivatives, method for the production and use thereof CURACYTE CHEMISTRY GMBH (DE) 2007-03-08 US disclosed
WO-2007026097-A1 NOVEL INDOLE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2007-03-08 WO disclosed
WO-2006102760-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2006-10-05 WO disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2004101507-A2 N-SULPHONYLATED AMINO ACID DERIVATIVES AND USE THEREOF AS MATRIPTASE INHIBITORS CURACYTE CHEMISTRY GMBH (DE) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 ALDH1A1 2924/4885GAA 1692/4885HPGD 2329/4885
US-12030857-B2 Glucose uptake inhibitors SLC2A1, SLC2A4, SLC2A2 ALDH1A1 1422/4885GAA 332/4885HPGD 3643/4885
US-20070055065-A1 N-sulphonylated amino acid derivatives, method for the production and use thereof DNPEP, ANPEP, PEPD ALDH1A1 1899/4885GAA 597/4885HPGD 644/4885
US-20070191447-A1 Novel heterocyclic compound OPRD1, GRIN3A, GRM3 ALDH1A1 1154/4885GAA 4565/4885HPGD 959/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A ALDH1A1 3748/4885GAA 2866/4885HPGD 1641/4885
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF LRRK2, PINK1, PARK7 ALDH1A1 4316/4885GAA 536/4885HPGD 3805/4885
US-20100137299-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS TRPV3, TRPV1, TRPC3 ALDH1A1 1020/4885GAA 3403/4885HPGD 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.